In particular, a genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort identified 11 MDGA2 SNPs that were significantly associated with the outcome at a genome-wide significant level.44 Furthermore, MDGA2 was identified as a potential neuroticism-related gene in a genome-wide association study,45 a finding that was subsequently replicated and extended by demonstrating association with a fatigability and asthenia subscale of harm avoidance.46 Thus, further investigation of the role of MDGA2 in depression and SSRI-treatment response is warranted. This evidence concerns the gene MDGA2 and sexual dysfunction.